Title |
The IGF1 P2 promoter is an epigenetic QTL for circulating IGF1 and human growth
|
---|---|
Published in |
Clinical Epigenetics, March 2015
|
DOI | 10.1186/s13148-015-0062-8 |
Pubmed ID | |
Authors |
Meriem Ouni, Yasemin Gunes, Marie-Pierre Belot, Anne-Laure Castell, Delphine Fradin, Pierre Bougnères |
Abstract |
Even if genetics play an important role, individual variation in stature remains unexplained at the molecular level. Indeed, genome-wide association study (GWAS) have revealed hundreds of variants that contribute to the variability of height but could explain only a limited part of it, and no single variant accounts for more than 0.3% of height variance. At the interface of genetics and environment, epigenetics contributes to phenotypic diversity. Quantifying the impact of epigenetic variation on quantitative traits, an emerging challenge in humans, has not been attempted for height. Since insulin-like growth factor 1 (IGF1) controls postnatal growth, we tested whether the CG methylation of the two promoters (P1 and P2) of the IGF1 gene is a potential epigenetic contributor to the individual variation in circulating IGF1 and stature in growing children. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Sweden | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 35 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 7 | 20% |
Student > Ph. D. Student | 6 | 17% |
Student > Bachelor | 4 | 11% |
Student > Doctoral Student | 3 | 9% |
Other | 2 | 6% |
Other | 8 | 23% |
Unknown | 5 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 10 | 29% |
Biochemistry, Genetics and Molecular Biology | 7 | 20% |
Medicine and Dentistry | 4 | 11% |
Nursing and Health Professions | 2 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Other | 3 | 9% |
Unknown | 8 | 23% |